ABA-101 not checked

Abata Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy”In the company’s words, NCT06566261 on ClinicalTrials.gov
Tested for
Progressive Multiple Sclerosis
Main trialPhase 1
“This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.”In the company’s words, NCT06566261 on ClinicalTrials.gov

Other drugs for Progressive Multiple Sclerosis

All 19 drugs for Progressive Multiple Sclerosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Feb 2026 ABA-101 in Participants With Progressive Multiple Sclerosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ABA-101

Following is part of Solo: you see every change to ABA-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in